查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1737151

全球纤维蛋白原浓缩物市场规模（依产品、应用、区域范围、预测）

Global Fibrinogen Concentrates Market Size By Product (Animal Fibrinogen Concentrates, Human Fibrinogen Concentrate), By Application (Congenital Fibrinogen Deficiency, Surgical Procedures), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

纤维蛋白原浓缩物市场规模与预测

2024 年纤维蛋白原浓缩物市场规模价值 31.1 亿美元，预计到 2032 年将达到 46.3 亿美元，2026 年至 2032 年的复合年增长率为 5.64%。

由于血液相关疾病在人群中的盛行率不断上升，以及人们对纤维蛋白原浓缩物的接受度不断提高，预计纤维蛋白原浓缩物市场将显着增长。全球纤维蛋白原浓缩物市场报告对市场进行了全面评估，全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的关键因素。

定义全球纤维蛋白原浓缩物市场

纤维蛋白原是一种存在于血浆中的糖蛋白，由肝臟产生。纤维蛋白原存在于脊椎动物体内，有助于血块的形成。但纤维蛋白原含量低会导致血管内形成血块，进而引发血栓症，阻碍血液在循环系统中的正常流动。纤维蛋白原会降低血液中的纤维蛋白原浓度，进而导致血块的形成。血栓症是一种罕见的出血性疾病，其特征为轻度至严重出血。纤维蛋白原缺乏症有三种：低纤维蛋白原血症、无纤维蛋白原血症、纤维蛋白原缺乏症。如果患者大量出血，纤维蛋白原浓度会增加整个血块的硬度，减少术后输血需求。

全球纤维蛋白原浓缩物市场概况

在这个竞争激烈的世界，由于生活方式的改变，人们的压力不断增加，导致血液相关疾病的发生率上升。据估计，先天性纤维蛋白原在该市场中占据最大份额，这有助于降低血友病的发生率，并催生出更优质的纤维蛋白原产品。纤维蛋白原浓缩物在先天性纤维蛋白原缺乏症等出血相关疾病患者中的使用日益增多，是推动该市场成长的主要因素。如今，人们的健康意识日益增强，将健康放在首位也是推动该市场成长的关键因素。

目前，纤维蛋白原浓缩物正被个人和企业广泛接受，以取代传统的纤维蛋白原来源，包括冷冻血浆和冷沉淀。由于患者人数的增加以及各种外科手术的使用导致对纤维蛋白原的需求增加，纤维蛋白原浓缩物市场正在成长。此外，纤维蛋白原浓缩物也用于製备抗凝血剂，用于治疗先天性无纤维蛋白原血症、纤维蛋白原血症、低纤维蛋白原血症等。

目录

第一章全球纤维蛋白原浓缩物市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

4. 纤维蛋白原浓缩物的全球市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球纤维蛋白原浓缩物市场（按产品）

  • 概述
  • 动物纤维蛋白原浓缩物
  • 人类纤维蛋白原浓缩物

6. 全球纤维蛋白原浓缩物市场（依应用）

  • 概述
  • 先天性纤维蛋白原缺乏症
  • 手术程序

7. 全球纤维蛋白原浓缩物市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

8. 全球纤维蛋白原浓缩物市场竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第九章 公司简介

  • CSL Behring
  • LFB Group
  • ProFibix BV
  • Baxter International Inc.
  • Hualan Biological Engineering
  • Harbin Pacific Biopharmaceutical Co. Ltd
  • Green Cross Limited
  • Shanghai Xinxing Medicine Co. Ltd.
  • Green Cross Limited
  • Shanghai Xinxing Medicine Co. Ltd.

第十章 附录

  • 相关调查
简介目录
Product Code: 54481

Fibrinogen Concentrates Market Size And Forecast

Fibrinogen Concentrates Market size was valued at USD 3.11 Billion in 2024 and is projected to reach USD 4.63 Billion by 2032, growing at a CAGR of 5.64% during the forecast period 2026-2032.

The Fibrinogen Concentrates Market is expected to show considerable growth owing to increasing blood-related disorders among people and growing acceptance of people for Fibrinogen Concentrate. The Global Fibrinogen Concentrates Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Fibrinogen Concentrates Market Definition

Fibrinogen is a glycoprotein present in the blood plasma and this is produced by the liver. Fibrinogen is present in the vertebrates which helps in the formation of a blood clot, sometimes blood clot is formed inside the blood vessels because of a low level of fibrinogen which leads to thrombosis and this interrupts the normal blood flow through the circulatory system. It is also helpful for making medicines for the disease-related blood. Thrombosis is an infrequent bleeding disorder that can be characterized by mild to critical forms of bleeding. The three forms of fibrinogen deficiency are hypofibrinogenemia, afibrinogenemia, and dysfibrinogenemia. When the patient is heavily bleeding the fibrinogen concentration enhances the whole blood clot rigidness and decreases the postoperative transfusion requirements.

Global Fibrinogen Concentrates Market Overview

In this competitive world, there is increasing stress among the people due to changes in their lifestyle as a result of this there is an increase in blood-related disorders, Congenital Fibrinogen is estimated to hold the largest share of this market which results in a better occurrence of hemophilia and better fibrinogen products. Increasing the use of fibrinogen concentrates for patients with the disease-related to bleeding such as congenital deficiencies is the primary factor driving the growth of this market. Nowadays people are more aware of their health and consider health their first priority is another important factor driving the growth of this market.

Presently, instead of traditional fibrinogen sources including frozen plasma or cryoprecipitate, Fibrinogen Concentrate is broadly being accepted by the people along with the firms. The Fibrinogen Concentrates Market is increasing due to the growing patient population and use of various surgical procedures which has led to the increased demand for Fibrinogen. Moreover, The Fibrinogen concentrates are being utilized to prepare anti-coagulates which are used in the treatment of congenital afibrinogenemia, dysfibrinogenemia, hypofibrinogenemia, and others.

Global Fibrinogen Concentrates Market: Segmentation Analysis

The Global Fibrinogen Concentrates Market is Segmented on the basis of Product, Application, and Geography.

Fibrinogen Concentrates Market, By Product

  • Animal Fibrinogen Concentrates
  • Human Fibrinogen Concentrates

Based on Product, the market is segmented into Animal Fibrinogen Concentrates and Human Fibrinogen Concentrate. Human Fibrinogen Concentrate is estimated to hold the largest share of this segment during the forecasted period due to the increasing requirement for fibrinogen concentrate to treat bleeding disorders and congenital coagulation deficiencies.

Fibrinogen Concentrates Market, By Application

  • Congenital Fibrinogen Deficiency
  • Surgical Procedures
  • ased on Application, the market is segmented into Congenital Fibrinogen Deficiency and Surgical Procedures. Congenital Fibrinogen is estimated to show the highest growth during the forecasted period owing to high incidences of hemophilia and increasing bleeding disorders among people. The safety proven by fibrinogen concentrates and advancements in fibrinogen products has also led to the growth of this segment in the Fibrinogen Concentrates Market.

Fibrinogen Concentrates Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of regional analysis, the Global Fibrinogen Concentrates Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is estimated to hold the largest share of this market because of the increasing burden of bleeding disorders and growing geriatric population and acquired hemophilia which is a rare autoimmune disorder is foremost in the geriatric population and a disease called Von Willebrand is one of the most common bleeding disorder which affects almost 1% of the population every year in the United States. These are the major factors contributing to the growth of the Fibrinogen Concentrates Market in this region.

Key Players

The "Global Fibrinogen Concentrates Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are CSL Behring, LFB Group, ProFibix BV, Baxter International Inc., Hualan Biological Engineering, Harbin Pacific Biopharmaceutical Co. Ltd, Green Cross Limited, and Shanghai Xinxing Medicine Co. Ltd. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • December 2021 - LFB plasma which is a part of LFB Group announced its acquisition of Immuno Tek Bio Centre in Florence, South California. LFB Group is a global biopharmaceutical company that develops and provides plasma-derived and recombinant products through its innovative technologies.
  • January 2022 - GC Cell and Rivaara Immune Private Limited announced that they are about to enter into an exclusive licensing agreement, Rivaara Immune has agreed to develop and commercialize Immunecell-LC.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL FIBRINOGEN CONCENTRATES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL FIBRINOGEN CONCENTRATES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL FIBRINOGEN CONCENTRATES MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Animal Fibrinogen Concentrate
  • 5.3 Human Fibrinogen Concentrate

6 GLOBAL FIBRINOGEN CONCENTRATES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Congenital Fibrinogen Deficiency
  • 6.3 Surgical Procedures

7 GLOBAL FIBRINOGEN CONCENTRATES MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East & Africa

8 GLOBAL FIBRINOGEN CONCENTRATES MARKET, BY COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 CSL Behring
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 LFB Group
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 ProFibix BV
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Baxter International Inc.
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Hualan Biological Engineering
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Harbin Pacific Biopharmaceutical Co. Ltd
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Green Cross Limited
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Shanghai Xinxing Medicine Co. Ltd.
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Green Cross Limited
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Shanghai Xinxing Medicine Co. Ltd.
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Appendix

  • 10.1 Related Research